Business Wire

GSMA and Mobile World Capital Barcelona Announce Return of YoMo to Mobile World Congress 2018

Del

The GSMA and the Mobile World Capital Barcelona today announced that The Youth Mobile Festival Barcelona (YoMo Barcelona) will return to Mobile World Congress 2018 after its hugely successful launch in 2017. YoMo Barcelona will once again inspire future generations to pursue education and careers in science, technology, engineering, art/design, and math (STEAM) disciplines. YoMo Barcelona will be held 26 February – 1 March 2018 at Fira Montjuïc.

“After an incredibly successful launch in 2017, where more than 11,000 young people and 3,000 educators from across Catalonia and Spain attended YoMo, we are delighted to host YoMo again as part of Mobile World Congress 2018,” said John Hoffman, CEO, GSMA Ltd. “YoMo showcases the passion, energy and excitement around science and technology and demonstrates how people across STEAM sectors are innovating and transforming our world. Through a fun and engaging atmosphere, thousands of school children get an ideal chance to learn about the careers opportunities available in the mobile and STEAM ecosystems.”

More than 17,000 students and 3,000 educators from across Catalonia and Spain will come to Barcelona to participate in this engaging and inspiring four-day showcase of science and technology, making it the largest STEAM event in Spain. Designed for students from 8 to 18 years old, YoMo Barcelona will feature educational exhibits, live shows, interactive workshops, and a wide range of hands-on activities. Information on activities currently scheduled for YoMo is available at www.yomobcn.com/showfloor.

YoMo is supported by local, regional, national and European stakeholders, including the Catalan Ministry of Education, businesses across STEAM industries, professional institutions, R&D laboratories, not-for-profit charities, universities and other specialist education institutions.

How to Participate in YoMo

YoMo Barcelona is open to all students and education professionals in Catalonia and Spain and is free to attend. Registration for YoMo will open in November; potential attendees can indicate interest in advance via the event website. More information, including how to register interest in attending YoMo, along with details on sponsorship and showcase opportunities, is available at www.yomobcn.com.

Get Involved at Mobile World Congress 2018

For more information on Mobile World Congress 2018, including how to attend, exhibit or sponsor, visit www.mobileworldcongress.com. Follow developments and updates on Mobile World Congress on Twitter @GSMA using #MWC18, on our LinkedIn Mobile World Congress page www.linkedin.com/company/gsma-mobile-world-congress or on Facebook at or on Facebook at www.facebook.com/mobileworldcongress/. For additional information on GSMA social channels, visit www.mobileworldcongress.com/social-media/.

The Mobile World Congress is the cornerstone of the Mobile World Capital, which will be hosted in Barcelona through 2023. The Mobile World Capital encompasses programmes and activities that span the entire year and will benefit not only the citizens of Barcelona, Catalonia and Spain, but also the worldwide mobile industry. For more information on the Mobile World Capital, visit www.mobileworldcapital.com.

-ENDS-

About the GSMA

The GSMA represents the interests of mobile operators worldwide, uniting nearly 800 operators with more than 300 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces industry-leading events such as Mobile World Congress, Mobile World Congress Shanghai, Mobile World Congress Americas and the Mobile 360 Series of conferences.

For more information, please visit the GSMA corporate website at www.gsma.com. Follow the GSMA on Twitter: @GSMA.

About Mobile World Capital Barcelona

Mobile World Capital Barcelona (MWCapital) is an initiative driving the mobile and digital transformation of society while helping improve people’s lives globally. With support of the public and private sector throughout Barcelona, Catalonia and Spain, MWCapital focuses on three areas: the digital empowerment of new generations, professionals and citizens; the digital transformation of industries; and the acceleration of digital innovation through entrepreneurship.

Collectively, our mSchools, Digital Transformation and mVenturesBcn programmes are positively transforming the education system, the industry and the economy. MWCapital also hosts the Mobile World Congress and delivers 4 Years From Now (4YFN), a business platform for the startup community.

Contact information

Media:
For the GSMA
Gloria Almirall, +34 93 236 09 00
galmirall@webershandwick.com
or
Pau Guerrero, +34 93 236 09 01
pguerrero@webershandwick.com
or
GSMA Press Office
pressoffice@gsma.com
or
For Mobile World Capital Barcelona
Marc Fernández, +34 93 515 7359
marcfernandez@mobileworldcapital.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30Pressemelding

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent

Manchester United and True Religion Launch Denim Range19.10.2018 17:37Pressemelding

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10Pressemelding

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an

Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene19.10.2018 11:54Pressemelding

Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF in patients aged 12 to <24 months, who have specific mutations in the CFTR gene. “Cystic fibrosis is a chronic, progressive disease that is present at birth, with symptoms often occurring in infancy, so early treatment is crucial to deliver the best possible outcomes for patients,” said Reshma Kewalr

Schlumberger Announces Third-Quarter 2018 Results19.10.2018 11:00Pressemelding

Schlumberger Limited (NYSE: SLB) today reported results for the third quarter of 2018. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2018 Jun. 30, 2018 Sept. 30, 2017 Sequential Year-on-year Revenue $8,504 $8,303 $7,905 2% 8% Pretax operating income $1,152 $1,094 $1,059 5% 9% Pretax operating margin 13.5% 13.2% 13.4% 36 bps 15 bps Net income - GAAP basis $644 $430 $545 50% 18% Net income, excluding charges & credits* $644 $594 $581 8% 11% Diluted EPS - GAAP basis $0.46 $0.31 $0.39 48% 18% Diluted EPS, excluding charges & credits* $0.46 $0.43 $0.42 7% 10% North America revenue $3,189 $3,139 $2,602 2% 23% International revenue $5,215 $5,065 $5,147 3% 1% North America revenue, excluding Cameron $2,572 $2,546 $2,086 1% 23% International revenue, excluding Cameron $4,559 $4,387 $4,430 4% 3% *These are non-GAAP financial measures. See section below entitled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commented, “Our third